Alba A Brandes Selected Research

Radiotherapy

1/2023	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
10/2022	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.
1/2022	Immune-checkpoint inhibitors in pituitary malignancies.
1/2022	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
1/2021	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
8/2020	Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients.
1/2019	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
1/2019	Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
12/2018	The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria.
5/2018	Temozolomide rechallenge in recurrent glioblastoma: when is it useful?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alba A Brandes Research Topics

Disease

62	Glioblastoma (Glioblastoma Multiforme) 10/2023 - 01/2002
58	Neoplasms (Cancer) 10/2023 - 05/2002
25	Glioma (Gliomas) 01/2021 - 05/2002
17	Disease Progression 01/2020 - 02/2003
14	Brain Neoplasms (Brain Tumor) 10/2022 - 05/2002
9	Oligodendroglioma 01/2019 - 06/2006
8	Astrocytoma (Pilocytic Astrocytoma) 03/2024 - 12/2003
8	Breast Neoplasms (Breast Cancer) 11/2020 - 09/2004
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017 - 05/2009
6	Medulloblastoma 12/2019 - 10/2003
3	Cognitive Dysfunction 01/2019 - 05/2004
3	Neoplasm Metastasis (Metastasis) 09/2017 - 10/2004
2	Thrombocytopenia (Thrombopenia) 01/2023 - 09/2014
2	Lymphopenia (Lymphocytopenia) 01/2021 - 09/2014
2	Vomiting 01/2020 - 12/2007
2	Nausea 01/2020 - 12/2007
2	Necrosis 11/2019 - 11/2013
2	Adenocarcinoma of Lung 01/2017 - 01/2017
2	Fatigue 11/2016 - 05/2015
2	Colorectal Neoplasms (Colorectal Cancer) 05/2016 - 05/2014
2	Neutropenia 05/2015 - 09/2014
2	Lymphoma (Lymphomas) 04/2014 - 10/2009
1	Central Nervous System Neoplasms 01/2022
1	Adenoma (Adenomas) 01/2022
1	Pituitary Neoplasms (Pituitary Adenoma) 01/2022
1	Meningioma (Meningiomas) 01/2021
1	Seizures (Absence Seizure) 08/2020
1	Epilepsy (Aura) 08/2020
1	Head and Neck Neoplasms (Head and Neck Cancer) 12/2017
1	Primary Ovarian Insufficiency 05/2017
1	Infertility (Sterility) 05/2017
1	Infections 11/2016

Drug/Important Bio-Agent (IBA)

49	Temozolomide (Temodar)FDA LinkGeneric 03/2024 - 01/2002
21	Bevacizumab (Avastin)FDA Link 10/2023 - 10/2009
20	Lomustine (CCNU)FDA Link 10/2023 - 02/2003
12	Procarbazine (Matulane)FDA Link 10/2022 - 01/2002
12	Vincristine (Oncovin)FDA LinkGeneric 10/2022 - 01/2002
10	Biomarkers (Surrogate Marker)IBA 10/2023 - 10/2003
8	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2023 - 11/2013
6	Trastuzumab (Herceptin)FDA Link 11/2020 - 08/2007
6	MethyltransferasesIBA 04/2018 - 10/2006
5	ErbB Receptors (EGF Receptor)IBA 01/2017 - 02/2008
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2014 - 02/2007
4	NivolumabIBA 01/2023 - 12/2017
3	Hormones (Hormone)IBA 11/2020 - 09/2004
3	Monoclonal AntibodiesIBA 09/2017 - 12/2009
3	Angiogenesis InhibitorsIBA 08/2017 - 05/2011
3	DNA (Deoxyribonucleic Acid)IBA 10/2016 - 10/2006
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2014 - 03/2009
2	pembrolizumabIBA 01/2022 - 12/2017
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
2	MicroRNAs (MicroRNA)IBA 11/2021 - 11/2015
2	taxaneIBA 11/2020 - 06/2015
2	PlatinumIBA 12/2017 - 05/2015
2	LY-2157299IBA 05/2017 - 01/2016
2	Transforming Growth Factors (Transforming Growth Factor)IBA 05/2017 - 01/2016
2	Phosphotransferases (Kinase)IBA 05/2017 - 01/2016
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2017 - 02/2007
2	Tyrosine Kinase InhibitorsIBA 01/2017 - 02/2010
2	fotemustine (Muphoran)IBA 01/2016 - 09/2009
2	Lapatinib (GW572016)FDA Link 11/2013 - 02/2010
2	O-(6)-methylguanineIBA 03/2010 - 10/2006
2	Carmustine (FIVB)FDA Link 03/2009 - 12/2004
2	Imatinib Mesylate (Gleevec)FDA Link 10/2008 - 12/2003
2	Cisplatin (Platino)FDA LinkGeneric 07/2005 - 05/2004
2	thiamine triphosphorate (TTP)IBA 02/2003 - 01/2002
1	RNA (Ribonucleic Acid)IBA 03/2024
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2023
1	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2022
1	IpilimumabIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2022
1	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2022
1	Growth Hormone (Somatotropin)IBA 01/2022
1	Contrast MediaIBA 12/2021
1	GadoliniumIBA 12/2021
1	regorafenibIBA 01/2021
1	AnthracyclinesIBA 11/2020
1	Biological FactorsIBA 11/2019
1	Indicators and Reagents (Reagents)IBA 01/2019
1	human ERBB2 proteinIBA 12/2018
1	Genetic Markers (Genetic Marker)IBA 01/2018
1	Codon (Codons)IBA 01/2018
1	AntibodiesIBA 12/2017
1	sonidegibIBA 10/2017
1	Glial Fibrillary Acidic ProteinIBA 05/2017
1	Chemokine CCL22IBA 05/2017
1	LigandsIBA 01/2017
1	onartuzumabIBA 01/2017
1	Gefitinib (Iressa)FDA Link 01/2017

Therapy/Procedure

51	Radiotherapy 01/2023 - 01/2002
48	Drug Therapy (Chemotherapy) 01/2023 - 05/2002
31	Therapeutics 11/2020 - 05/2002
5	Chemoradiotherapy 01/2020 - 05/2008
4	Adjuvant Chemotherapy 12/2007 - 02/2003
3	Immunotherapy 12/2017 - 11/2015
3	Salvage Therapy 09/2009 - 07/2005
2	Adjuvant Radiotherapy 01/2021 - 03/2005
2	Aftercare (After-Treatment) 01/2020 - 12/2007
1	Drug Tapering 01/2023